ClinicalTrials.gg
TerminatedNCT01280565Updated Nov 5, 2020

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

A Phase 3 interventional study of Masitinib and Dacarbazine in Metastatic Melanoma, sponsored by AB Science. Terminated at 9 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-05.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision based on portfolio prioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 362 studies in Melanoma with a site in France — 47 open to participants now, 92 under way, 21 of them phase 3. Melanoma · France.

Enrollment
153rd of 301
134 · median 138
Started
2011
with 14 others
Phase 3
75 of 362
5 open now
Registered
49th of 362
by date

Among the 362 studies in Melanoma with a site in France, this one is the 153rd largest by enrollment of the 301 interventional ones that give a count, is one of 15 that started in 2011, is one of 75 in phase 3, and was the 49th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

47 of the 362 studies in Melanoma with a site in France are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 362 studies in Melanoma with a site in France, or all of them as a file.
02

Study summary

The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit and who have not previously been treated for melanoma.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor with potent activity against the juxta membrane domain of c-Kit. Masitinib is also thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective of this study was to evaluate the efficacy and safety of masitinib with respect to dacarbazine in the treatment of non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit. Following a protocol amendment, the dacarbarzine treatment group was closed and recruitment restricted to masitinib treatment of chemo-naïve (first-line) patients.

03

Conditions studied

  • Metastatic Melanoma

Browse trials for

Keywords

  • Melanoma
  • Tyrosine kinase inhibitor
  • c-Kit juxta membrane mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria include:

  • Patient with or cytologically confirmed non-resectable or stage 3 (non-resectable IIIB or IIIC, AJCC TNM staging system 7th edition) or stage 4 melanoma
  • Patient with detectable c-Kit JM mutation (mutation in exon 9, 11 or 13) confirmed by DNA or RNA sequencing, which is expected to be mainly found after screening of mucosal or acral melanoma or melanoma on skin with chronic sun-induced damages (defined by a microscopically marked elastosis involving the skin surrounding their primary melanoma).
  • Patient not previously treated for melanoma ()

Main exclusion criteria include:

  • Pregnant, or nursing female patient
  • Patient with active .
  • Prior treatment with a tyrosine kinase c-Kit inhibitor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Masitinib

    Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.

    Drug: Masitinib

  • Active comparator
    Dacarbazine

    Participants receive dacarbazine, given via IV bolus at 1,000 mg/m2 once every 3 weeks. Following a protocol amendment, the dacarbarzine treatment group has been closed

    Drug: Dacarbazine

Interventions

  • Masitinib 7.5 mg/kg/day

    Also known as: AB1010

  • IV bolus at 1,000 mg/m2 once every 3 weeks

    Also known as: DTIC

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Estimated as the number of patients with documented partial response or complete response defined according to the RECIST criteria, divided by the number of randomized patients

    Time frame: 24 weeks

Secondary outcomes

  1. PFS

    Progression Free Survival (PFS) is defined as the delay between the date of randomization to the date of documented progression (according to RECIST) or any cause of death during the study.

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

  2. Overall Survival (OS)

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to death, assessed for a maximum of 60 months

07

Study locations

9 sites
  • Blumenthal Cancer Centre
    Charlotte, North Carolina 28204, United States
  • University Hospital Hradec Králové
    Hradec Králové, 500 12, Czechia
  • Hôpital Saint Andre
    Bordeaux, 33075, France
  • Centre Hospitalier LE MANS
    Le Mans, 72037, France
  • Hôpital Sainte Marguerite
    Marseille, 13274, France
  • Klinik und Poliklinik für Hautkrankheiten
    Münster, 48149, Germany
  • Istituto Europeo di Oncologia
    Milano, 20141, Italy
  • N.N.Blokhin Russian Cancer Research Centre
    Moscow, 115478, Russian Federation
  • Hospital General de Valencia
    Valencia, 46014, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Aug 2019, 103 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2010
First posted
Jan 21, 2011
StartActual
Jan 2011
Primary completionActual
Aug 2019
CompletionActual
Aug 2019
Results delay requested
Nov 3, 2020
Last update
Nov 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01280565
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jan 21, 2011
Start date
Jan 2011
Primary completion
Aug 2019
Completion
Aug 2019
Last update
Nov 5, 2020

Study contacts

Jean-Jacques GROB, MD, PhD
principal investigator · Hôpital Sainte Marguerite, Marseille, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion